Veterinärmedizinische Universität Wien Forschungsinformationssystem VetDoc

Grafischer Link zur Startseite der Vetmeduni Vienna

Gewählte Publikation:

Open Access Logo

Publikationstyp: Zeitschriftenaufsatz
Dokumenttyp: Originalarbeit

Jahr: 2017

AutorInnen: Hadzijusufovic, E; Albrecht-Schgoer, K; Huber, K; Hoermann, G; Grebien, F; Eisenwort, G; Schgoer, W; Herndlhofer, S; Kaun, C; Theurl, M; Sperr, WR; Rix, U; Sadovnik, I; Jilma, B; Schernthaner, GH; Wojta, J; Wolf, D; Superti-Furga, G; Kirchmair, R; Valent, P

Titel: Nilotinib-induced vasculopathy: identification of vascular endothelial cells as a primary target site.

Quelle: Leukemia. 2017; 31(11):2388-2397



Autor/innen der Vetmeduni Vienna:

Grebien Florian
Hadzijusufovic Emir

Beteiligte Vetmed-Organisationseinheiten
Universitätsklinik für Kleintiere, Klinische Abteilung für Interne Medizin Kleintiere


Abstract:
The BCR/ABL1 inhibitor Nilotinib is increasingly used to treat patients with chronic myeloid leukemia (CML). Although otherwise well-tolerated, Nilotinib has been associated with the occurrence of progressive arterial occlusive disease (AOD). Our objective was to determine the exact frequency of AOD and examine in vitro and in vivo effects of Nilotinib and Imatinib on endothelial cells to explain AOD-development. In contrast to Imatinib, Nilotinib was found to upregulate pro-atherogenic adhesion-proteins (ICAM-1, E-selectin, VCAM-1) on human endothelial cells. Nilotinib also suppressed endothelial cell proliferation, migration and tube-formation and bound to a distinct set of target-kinases, relevant to angiogenesis and atherosclerosis, including angiopoietin receptor-1 TEK, ABL-2, JAK1 and MAP-kinases. Nilotinib and siRNA against ABL-2 also suppressed KDR expression. In addition, Nilotinib augmented atherosclerosis in ApoE-/- mice and blocked reperfusion and angiogenesis in a hindlimb-ischemia model of arterial occlusion, whereas Imatinib showed no comparable effects. Clinically overt AOD-events were found to accumulate over time in Nilotinib-treated patients. After a median observation-time of 2.0 years, the AOD-frequency was higher in these patients (29.4%) compared to risk factor- and age-matched controls (<5%). Together, Nilotinib exerts direct pro-atherogenic and anti-angiogenic effects on vascular endothelial cells, which may contribute to development of AOD in patients with CML.

Keywords Pubmed: Adult
Aged
Aged, 80 and over
Animals
Apolipoproteins Egenetics
Atherosclerosischemically induced
Endothelium, Vascularcytologydrug effects
Female
Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positivedrug therapypathology
Male
Mice
Mice, Inbred C57BL
Mice, Knockout
Middle Aged
Protein Kinase Inhibitorsadverse effects
Pyrimidinesadverse effects
Vascular Diseaseschemically induced

© Veterinärmedizinische Universität Wien Hilfe und DownloadsErklärung zur Barrierefreiheit